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A B S T R A C T
Intense research activity in HPV modelling over this decade has prompted the development of additional
guidelines to those for general modelling. A specific framework is required to address different policy questions
and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and
quality-based framework for epidemiologic and economic HPV models. Its development involved an established
process. Reporting standards have been structured according to seven domains reflecting distinct policy ques-
tions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-
relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vacci-
nation in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for in-
dividuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations
applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination
approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the
development of models in accordance with an explicit framework, to better enable target audiences to under-
stand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the
model's contribution to informed decision-making.
1. Introduction
Infection with oncogenic types of the human papillomavirus (HPV)
has been causally linked to cervical cancer, the fourth most common
cancer in women worldwide, with an estimated 569,847 new cases
being diagnosed in 2018 [1]. HPV is also associated with a varying
proportion of cancers at other anogenital and oropharyngeal sites in
both women and men, with the total HPV-attributable cases in 2012
estimated as 630,000 [2]. HPV is additionally responsible for anogen-
ital warts, a debilitating and embarrassing condition for many, as well
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as recurrent respiratory papillomatosis (RRP), an uncommon condition
of recurrent growth of wart-like lesions in the respiratory tract. Al-
though it is a rare disease {0.07–1.0 case per 100,000 children (juvenile
onset RRP) [3,4]; 0.54–4.0 cases per 100,000 adults (adult onset RRP)
[5,6]), in a small number of cases, RRP results in respiratory obstruc-
tion which can be life-threatening [7].
In the past decade, HPV vaccination of girls has been introduced in
many countries, with the objective of preventing cervical cancer de-
velopment later in life for women while also preventing HPV-related
cancers in men via herd protection (i.e. indirect protection of un-
vaccinated individuals from HPV infection due to others in the popu-
lation being protected by being vaccinated against HPV). Some coun-
tries have also introduced universal vaccination of boys and/or targeted
vaccination of men who have sex with men (MSM). In parallel, there
have been recent developments in screening methods (e.g. HPV testing)
and triage technology advances for screen-positive women, which are
leading to more effective secondary cervical cancer prevention pro-
grams. However, the full health gains in preventing cancer diagnoses
and deaths through screening and vaccination will only be observed
several decades after the initial implementation phase. Decision-ana-
lytic models of health prevention strategies have therefore been key to
supporting long-term predictions of health outcomes, resource utiliza-
tion and economic value for new interventions in primary and sec-
ondary prevention of HPV and related disease.
Due to the role of models and cost-effectiveness evaluations in
guiding health technology assessment and healthcare policy decision-
making, quality frameworks have been proposed to enable transpar-
ency, interpretation and credibility of results, and comparison between
similar studies. A quality framework attempts to address poorly de-
signed models, over-simplification, misinterpretation and failure to
appreciate the degree of uncertainty in a decision process [8]. Existing
frameworks for modelling, e.g. the International Society of Pharmaco-
logical Outcomes Research (ISPOR) guidelines, provide a set of best
practices and relevant guidelines for general modelling [9]. However,
the publication of an increasingly large volume of modelling/cost-ef-
fectiveness analyses of HPV vaccination programs as well as screening
programs [10–18], a growing number of independent model types, and
the need to address different policy questions has resulted in intense
research activity in the area of HPV modelling over the last decade. In
addition, modelling HPV presents unique complexities including sexual
transmission, multiple HPV types with different natural histories, a
variety of HPV-related diseases, difficulty in studying the progression of
the disease to cancer (pre-cancerous lesions are detected by screening
and treated), multiple primary and secondary prevention tools, herd
protection effects resulting from vaccination, modification of natural
history due to screening and many levels of heterogeneity in sexual and
health-seeking behaviour. Therefore, in order to address distinct issues
related to HPV modelling a specific framework is required in addition to
existing guidelines.
Here, we present HPV-FRAME, an initiative to develop a consensus
statement and a quality framework in the form of a CONSORT-style
itemised checklist encapsulating agreed reporting standards for
epidemiological and economic models of interventions in HPV and
HPV-related cancer prevention. The framework does not consider
models for other purposes, such as biological models or conceptual
models which do not use real-world data. HPV-FRAME is specifically
oriented to policy evaluations, with the aim of allowing modelers, peer-
reviewers, journal editors and policy decision-makers to understand a
model's strengths and weaknesses in relation to a specific policy ques-
tion, thus improving the model's contribution to informed decision-
making. HPV-FRAME is not intended to be prescriptive about modelling
methods, but is designed to promote transparency in reporting those
methods, improve the completeness of reported evaluations, prevent
oversimplification and limit the number of poorly designed and re-
ported studies.
2. General principles of good modelling practice as they apply to
HPV evaluations
A number of key general principles of good modelling practice have
previously been agreed upon and disseminated, and some of these
specifically consider infectious diseases and HPV [9–19]. These general
principles provide a backbone for a high quality modelling study or
economic evaluation, and are briefly summarised in Table 1.
Model-based decision and cost-effectiveness analyses are usually
focused on evaluating policy-relevant questions. They need to explicitly
describe what decision-making process they inform, and accordingly,
justify their approach, including the range of options considered, the
type of evaluation, and methodological assumptions such as the per-
spective used. If there are more than two intervention options, a full
incremental analysis should be conducted. National and international
guidelines for economic evaluations should generally be followed, with
justification for any deviations.
The choice of a model should be determined by best practice
guidelines. In general terms, model structures and parameterization
should be as parsimonious as possible, while being able to capture the
essential elements of the decision and mindful of the availability of
data. Dynamic models should be used unless it can be demonstrated
that herd effects are unimportant to the decision being informed
[19–23]. This is because dynamic transmission models explicitly si-
mulate changing (declining) HPV incidence and prevalence for vaccine-
included types over time, and the consequently declining risk of new
infections, after population-wide vaccination initiatives are introduced.
Other types of models should ensure that declining incidence/pre-
valence of vaccine-included types after vaccination are effectively si-
mulated. Static models should only be used when both (i) a con-
servative (i.e. under-estimated) measure of impact or value for money is
sufficient (e.g. a static model may underestimate total health and
monetary benefits of vaccination in which case it cannot be used to rule
out a vaccination intervention that is found not to be cost-effective);
and (ii) when the analysis does not include comparisons between
multiple interventions with herd effects (which cannot be captured by
static models), such as is often the case in HPV vaccine evaluations – for
example, catch-up vaccination versus no catch-up, both sexes versus
Table 1
Summary of general principles of good modelling practice.
Principle Reference
The type and scope of the economic or epidemiological evaluation should fit the requirements of the decision maker. [20,21]
Dynamic models should be used unless it can be demonstrated that herd effects are unimportant. [19–21]
Publications should include: results stratified by subgroup (e.g. age or sex), health outcomes in natural units, intermediate outcomes (e.g. pre-cancerous lesions) and
sexual mixing assumptions.
[21,23]
Goodness of fit to data should be shown where appropriate.a [22,23]
Sensitivity analysis (considering whether a probabilistic approach is appropriate) should be used and should include the discount rate. [20–23]
All diseases that are relevant to the intervention should be incorporated. [23]
a How the authors describe and document these aspects should be a decision they make. For example, some authors choose to develop online webpages which
provide an enduring reference for subsequent publications. Another alternative is to utilise technical appendices and/or reference previous work as applicable.
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female-only, 3-dose versus 2-dose, nonavalent versus bivalent HPV
vaccines. Examples of relevant policy questions in HPV prevention, and
model types which are likely to be needed to adequately address each
question, are shown in Fig. 1.
A thorough review of available data should be performed to inform
model calibration. This review should span data on sexual behaviour,
HPV prevalence studies, cancer incidence and mortality data as ap-
propriate to the model, with a focus on extracting data from high-
quality studies only (e.g. IARC-reported registry data on cancer rates
should be used over unvalidated local hospital data on cancer rates),
and model fits across all relevant data sources should be provided. If
model parameters were fitted to observed data, then both graphical
(e.g. model outputs compared to data points) and numerical (e.g. de-
viance, Akaike Information Criterion) measures of goodness of fit
should be presented. If Bayesian methods were used then the posterior
distributions of fitted parameters should be well-described. Wherever
possible, fitted or otherwise parameterized models should be validated
by comparing predictions to outcomes not used for parameterization.
Reported outcomes should include main disease outcomes and dis-
ease-specific outcomes in natural units (e.g. cancer cases), intermediate
endpoints if modelled (e.g. HPV prevalence, pre-cancerous lesions)
[21,23], long-term health outcomes [e.g. quality-adjusted life-years
(QALYs) or disability-adjusted life years (DALYs)] and economic out-
comes, if relevant (e.g. costs). Disaggregated outcomes by time and age
(both with and without discounting if appropriate) should be shown at
a minimum for the base case (in an appendix if necessary). The timing
of interventions, time horizon of the analysis, and indication of popu-
lation-based versus cohort-based outcomes should also be specified.
Probabilistic sensitivity analysis (PSA) is considered the preferable
approach for economic evaluations to assess the joint influence of un-
certain parameters on costs and cost-effectiveness outcomes.
Multivariate sensitivity analysis (MSA) for epidemiological models or a
best/worst case analysis at a minimum, should be considered for health
outcomes. Although univariate sensitivity analysis can provide some
insight into uncertainty, it does not take into account the total effect of
a combination of uncertain parameters and is therefore less preferable
than PSA/MSA for economic components. The choice of distributions
for PSA or prior distributions for Bayesian fitting algorithms should at a
minimum capture sampling uncertainty and not violate best practice
guidelines without justification.
Overall, it is important to note that models predict possible rather
than actual outcomes, ranging from best case to worst case scenarios
and that the predicted outcomes are dependent on the policy question
and the parameters defining it as well as the validity and rigour of the
data used in the model.
3. HPV-FRAME development process
The development of HPV-FRAME was informed by an established
process involving a 5-phase strategy with distinct activities (Table 2)
[24]. The need for a framework for HPV prevention modelling was first
identified at an International Papillomavirus Conference modelling
workshop in 2009 in Malmö, Sweden [23], and was also prompted by a
comprehensive review of the HPV modelling literature conducted for a
2012 Vaccine Monograph [25]. The HPV-FRAME Steering Committee
(KC, MJ, JK, SK, JB, RB and MB) met before the satellite session at the
International Papillomavirus Conference (IPVC) 2014 and identified the
preliminary domains of HPV-FRAME which were presented at in-
formation sessions held at international conferences (IPVC 2014,
Seattle, USA; EUROGIN 2015, Seville, Spain; IPVC 2015, Lisbon, Por-
tugal). Interested parties were identified via these conference in-
formation sessions and from a dedicated website established in 2015
(www.hpv-frame.org), and were asked to sign-up to a mailing list to be
kept informed of the progress of this initiative and contribute input. The
HPV-FRAME Steering Committee held a meeting at IPVC 2015 where
the structure of the framework sections was decided. These sections
were presented at a dedicated HPV-FRAME session at EUROGIN 2016
(Salzburg, Austria) and abstracts summarising the scope of each section
were posted on the website. Input from attendees was minuted and a
call for further submissions via the website was made. As a result of the
work at this stage, the domains were expanded in response to increasing
interest in certain areas (e.g. vaccination at older ages). The draft fra-
mework was developed and presented at a dedicated HPV-FRAME
session at IPVC 2017 (Cape Town, South Africa). The final framework is
presented here after interested parties (via the mailing list) were invited
to provide feedback on the content of this manuscript.
The focus of the framework is on the analysis of the effectiveness
and/or cost-effectiveness of interventions in cervical screening and HPV
vaccination which are designed to inform decision-making. There are
two key components to each domain in the framework: reporting key
Fig. 1. Model type and data requirements for example policy questions.*
*This schematic summarises general aspects of model construction. In practice, all model types can vary considerably in their complexity and data requirements.
K. Canfell, et al. Papillomavirus Research 8 (2019) 100184
3
structural inputs/parameters and reporting key outputs. Although the
framework is not prescriptive about which outputs should be reported,
researchers are encouraged to provide clarity on the outputs reported
and which subset of outputs are calibration or validation targets and
therefore presented against observational data. Modelers are en-
couraged to report by age and sex. An example application of the fra-
mework to a previously published analysis has been provided for se-
lected domains.
The reporting standards for HPV models have been structured ac-
cording to seven domains which reflect policy questions of topical in-
terest in HPV-related interventions. Domains have also been cate-
gorised by relevance to populations or evaluations (Table 3). A)
Population relevant domains are: HPV vaccination in pre-adolescent
and young adolescent females and/or males (Domain 1); additional
issues regarding HPV vaccination in older women and/or men (Domain
2); additional issues regarding targeted vaccination in men who have
sex with men (MSM) (Domain 3); HPV vaccination and/or cervical
cancer screening for individuals living with HIV (Domain 4); and spe-
cific considerations regarding HPV prevention in low and middle in-
come countries (LMIC) (Domain 5). B) Domains that are additional
considerations for evaluations applicable to specific interventions are:
cervical screening or integrated cervical screening and HPV vaccination
approaches (Domain 6); and additional issues regarding alternative
vaccine types (e.g. nonavalent), and alternative schedules (Domain 7).
Overall, reporting standards in all relevant domains should be ad-
dressed when reporting model inputs and outputs. For example an
evaluation of vaccination of pre-adolescent HIV positive men who have
sex with men in a low income country should consider the reporting
standards in Domain 1 (vaccination in adolescents), Domain 3 (targeted
vaccination in MSM), Domain 4 (evaluations for individuals living with
HIV), and Domain 5 (HPV prevention in LMIC). Furthermore, HPV-
FRAME core reporting standards (Table 4) should additionally be re-
ported for all models.
4. Domain 1. reporting modelled evaluations of HPV vaccination
in adolescent females and/or males
To date, a number of reviews of modelling/cost-effectiveness ana-
lyses of HPV vaccination programs [25] and a few guidelines for
modelling vaccination or infectious diseases in general [19,21,26] and
HPV vaccination in particular [20] have been published, which sum-
marize key conclusions about model results and methodological re-
commendations. Vaccinating girls prior to sexual debut has been re-
ported to be cost-effective at list prices for vaccines and commonly used
cost-effectiveness criteria [14–18,27]. However, in middle-income
countries with high vaccine prices, improving screening coverage has
been found to be more cost-effective than vaccination if lower prices are
not negotiated [27]. As vaccination and screening target different age-
cohorts, some argue that best practice to maximise impact and ensure
equity would be to introduce both strategies, even in LMIC [29,30].
A number of studies have shown that extending vaccination to
males is unlikely to be cost-effective unless prices (including delivery
costs) are extremely low and/or overall vaccine uptake in females is low
[11,12,15,17,28]. Other recent studies have found that when all HPV-
Table 2
The 5-step development process for HPV-FRAME.
Step Action Timeline
Initial steps Identify the need for a guideline
Review the literature
The need for a framework was identified via an expert discussion followed by a comprehensive review of the HPV
modelling literature conducted for a 2012 Vaccine Monograph.
2009–2013
Pre-meeting activities Identify participants• HPV-FRAME information sessions held at IPVC 2014 (Seattle), EUROGIN 2015 (Seville) and IPVC 2015 (Lisbon)• Interested parties asked to sign up to mailing list• Website and mailing list were established
Generate a list of items for consideration at the meeting• HPV-FRAME Steering Committee held a workshop at IPVC 2015 (Lisbon), to decide upon the structure of the
framework
2014–2015
Meeting – EUROGIN 2016 (Salzburg) Presentation of draft framework• Dedicated HPV-FRAME session held at EUROGIN – Input from attendees.• Abstracts summarising the scope of each section were posted on website.
2016
Meeting – IPVC 2017 (Cape Town) Presentation of the framework• Dedicated HPV-FRAME session at IPVC 2017 2017
Publication and post-publication
activities
Dissemination• Public consultation on manuscript draft: emailed to interested parties for comment.• Submission to journal• Inform other journal editors
Review framework regularly• Set up capacity for comments/input for next revision (via website)
2018 - ongoing
Table 3
Summary information on HPV-FRAME.
Domain No Target population Modelled strategy No of reporting standards
1 Adolescent females or/and males Vaccination 10 + CRS
2 Adult females and/or males Vaccination 6 + CRS
3 Men who have sex with men (any age) Vaccination 7 + CRS
4 Females or/and males living with HIV Vaccination and/or cervical cancer screening 6 + CRS
5 Females and/or males in low and middle income
countries
Vaccination and/or cervical cancer screening 3 + CRS
6 Females and/or males Cervical screening.
Integrated cervical screening and HPV vaccination
6 + CRS
5 + CRS
7 Females and/or males Vaccination using alternative vaccine types (e.g. nonavalent) or/and alternative
dose schedules
5 + CRS
CRS: core reporting standards (see Table 4).
K. Canfell, et al. Papillomavirus Research 8 (2019) 100184
4
related diseases are taken into account, cost-effectiveness estimates are
more favourable for both-sex vaccination [31,32]. However, while we
have a reasonable understanding of the natural history of HPV infec-
tions leading to high-grade intraepithelial neoplasia in the cervix based
on evidence accumulated through multiple prospective studies, this is
less true for other sites. There are unanswered questions related to the
development of natural immunity, latency and reactivation, the dura-
tion from HPV infection to invasive cancer, the prognostic relevance of
intermediate stages such as anal intraepithelial neoplasia (AIN) and
uncertain intermediate stages for oropharyngeal cancer. However, if
the intervention to be considered is vaccination, the interim natural
history before development of invasive disease may not need to be
specified in detail. When considering both-sex vaccination evaluations,
it should be noted that the context is usually female-only vaccination as
the comparator because most countries introduced female-only vacci-
nation first; cost-effectiveness will thus be dependent on the vaccine
coverage in girls and vaccine price. Recent evidence shows that list
prices are rarely paid in national or regional vaccination programs [33].
The actual price paid for vaccines at a regional or country level is often
an outcome of confidential tender negotiations and may not be avail-
able to use in an analysis; in this situation it is recommended that
threshold analysis be performed to determine the maximum price that
should be paid.
The key drivers of uncertainty in cost-effectiveness evaluations of
HPV vaccination are duration of vaccine protection [14,16,34], natural
immunity duration [34,35], model type (static/dynamic) [17,28],
vaccine effectiveness [28] (measured by how effective the vaccine is in
preventing persistent HPV-infection or HPV-related disease, or as ap-
plicable to the particular research question), comparators (screening/
no screening) [27,28,36], vaccine price [27,36], discount rate [14] and
HPV prevalence [14]. Furthermore, a recent meta-analysis of models
predicting the long-term population-level effectiveness of quadrivalent
vaccination in women and men found that key drivers of vaccination
impact include how models capture heterogeneity in mixing between
risk groups (e.g., age, level of sexual behaviour) and the level of natural
immunity among women [35]. Furthermore, involving relevant experts
(clinicians, policy makers, etc.) to help inform model assumptions
would be key to making sure that certain events are being modelled
appropriately and that the questions being answered are genuinely
policy-relevant.
HPV-FRAME reporting standards for models of adolescent female
and male vaccination in individuals ≤19 years of age, are presented in
Appendix Table A1. An economic evaluation of HPV vaccination in the
UK [37] is used as an example application (Appendix Table A2).
5. Domain 2 - additional issues in reporting vaccination in older
individuals
Vaccinating a larger segment of the population than has previously
been routinely performed, with a focus on vaccinating up to older ages
[38] is an emerging area of evaluation. Two sub-categories of this area
will be addressed in HPV-FRAME: i) untargeted vaccination of females
and/or males to older ages (similar in concept to an ‘extended catch-
up’) and ii) targeted strategies in HPV-negative individuals or those
who are negative for particular HPV types e.g. HPV16. The latter could
be achieved by integrating vaccination with HPV-based cervical
screening i.e. vaccinating only HPV negatives after screening while
referring HPV positive women for further management. This strategy
has the potential to improve cost-effectiveness by targeting vaccination
to those in the population who are most likely to benefit as they are not
infected with vaccine-included HPV types. This concept is sometimes
called “screen and vaccinate” [39,40].
Very little work modelling vaccination of older people has been
performed thus far. However, the original evaluations of female HPV
Table 4
HPV-FRAME core reporting standards.
a) Inputs Reported by age?
(Y/N)
Report by sex (F-only,
M-only or both)?
Comments
Target population for intervention Y Y Age group(s), female/male
Sexual behaviour Y (for dynamic
models)
Y Sexual behaviour inputs used e.g. number of partners, rate of partner change,
heterogeneity, duration of partnerships, number of sex acts per partnership or per
unit of time where modelled.
Inputs stratified by appropriate risk groups (e.g. by sexual activity, sex, age, sex of
partners, urban/rural if applicable) where modelled.
Assortativity of sexual mixing where modelled. Probability of HPV transmission per
partnership or per sex act
Cohort examined for evaluation/time
horizon
N N Are results presented for first vaccinated cohort, cohort at post-vaccination
equilibrium and/or what time horizon has been considered?
Quality of life assumptions If available If available
Calibration Y Y Calibration method(s) used
Values of goodness-of-fit metric(s)
Comparison of model outcomes with data points used to fit the model to (in either
tabular or graphical format), including credibility/uncertainty intervals or
distributions where relevant
Validation (where possible) Y Y Comparison of model outcomes with data points used to validate the model (in
either tabular or graphical format), including credibility/uncertainty intervals or
distributions where relevant
Costs If applicable If applicable Related to detection of disease and treatment. Parameter applicable only to
economic evaluations. Currency and year; methods for inflation adjustment.
b) Outputs Reported by age?
(Y/N)
Report by sex (F-only,
M-only or both)?
Report as calibration or validation target? (Y/N)
Cancer incidence, mortality, life years,
QALYs/DALYs (as appropriate)
Y Y Y
HPV prevalence, pre-intervention Y Y As appropriate to evaluation
CIN2 detected Y Y N
Sensitivity analysis on key inputs Y Y N
Incremental cost-effectiveness ratios and
costs saved
Only for economic evaluations
QALYs: quality-adjusted life-years.
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vaccination in relation to the optimal age of catch-up are very relevant
to evaluations of untargeted vaccination to older ages [33]. Some of the
original catch-up vaccination modelling literature was difficult to in-
terpret because a wide age range of vaccination was modelled. This
averaged out the costs and benefits across ages, and the specific age at
which catch-up became cost-ineffective was not apparent. The cost-ef-
fectiveness of catch-up campaigns to older ages is variable and depends
on the age distribution of sexual partnerships, vaccine price, uptake and
the threshold for cost-effectiveness [41]. Furthermore, an evaluation
will need to be done separately for females and males, since firstly, the
cost-effectiveness in males differs from females (given lower overall
disease burden) [13]; and secondly, cost-effectiveness depends on herd
effects from established vaccination programs in females.
A previous review of the literature in relation to modelling catch-up
noted that the validity of the conclusions about catch-up vaccination
and vaccination of older women depends on assumptions made about
exposure of each of the age cohorts to type-specific HPV infection, since
vaccination against a particular HPV type is maximally effective in
women who are HPV DNA negative for that type [13]. Also, appropriate
modelling of naturally-acquired immunity to infection strongly impacts
the calculation of vaccine effectiveness in catch-up cohorts; therefore, if
naturally-acquired immunity is not included in the model, then catch-
up vaccination appears more cost-effective. Therefore, well-calibrated
dynamic models should be equipped to simulate and explore various
assumptions around naturally-acquired HPV immunity, especially when
addressing the differential effects of catch-up vaccination.
HPV-FRAME reporting standards for evaluations of vaccinating
older people are presented in Appendix Table A3. Overall, for evalua-
tions of vaccinating older people it will be critical to understand a
model's assumption around the possibility of new infection in older
individuals progressing, naturally-acquired immunity, and re-emer-
gence of latent infections and their clinical meaning. These assumptions
will profoundly impact the modelled simulation of vaccine impact if
administered at older ages and hence impact cost-effectiveness. Since
this is an emerging area, no example application is presented.
6. Domain 3. additional issues for reporting modelled evaluations
of targeted HPV vaccination in men who have sex with men (MSM)
Models of HPV prevention in MSM differ from modelling HPV in-
fection in heterosexuals. HPV epidemiology has distinct features among
MSM with implications for transmission and control (e.g. higher
probability of co-infection with HIV, different pattern of age-de-
pendency in HPV prevalence). Selective vaccination of MSM may only
be realistically achieved after sexual debut which has implications for
vaccine delivery, effectiveness and impact. Thus, estimating the cost-
effectiveness of targeted vaccination of MSM requires additional con-
siderations compared to assessing the cost-effectiveness of vaccinating
all adolescent boys.
The burden of the disease needs to be assessed in advance and needs
to be made clear at the onset of any modelling analysis. However, es-
timating disease burden among MSM is hindered by sexual orientation
not being captured by cancer registries. The burden of anal cancer is
certainly higher among MSM than heterosexual males [42,43]. Cur-
rently, data on the natural history and epidemiology of HPV and HPV-
related disease among MSM are more limited than that for women.
Overall, there is still a large amount of uncertainty regarding the vac-
cine-preventable burden of disease in MSM.
Considerations for evaluations of HPV vaccination in males and in
older individuals (Domain 2) will also apply to evaluations of targeted
vaccination of MSM. In practice, the burden of disease that can be
prevented by vaccinating at an older age is a function of both an in-
dividual's past history of infection (and possible immunity), as well as
their risk of being infected in the future and of that infection progres-
sing to cancer. The MSM population in many high-income countries
with relevant data is typified by sustained high levels of partner change
and thus prior exposure to HPV may be high in a sexually active po-
pulation but risk of future infection is also potentially higher.
Furthermore, MSM have a higher risk of exposure to HIV and there is
evidence that the prevalence of oncogenic HPV is higher among HIV-
positive compared to HIV-negative MSM [44]. There is also evidence
that HIV-positive MSM have increased anal and penile oncogenic HPV
incidence rates, decreased anal clearance rates compared to HIV-ne-
gative MSM [45–48], and increased risk of anal cancer [49]. For models
which include HIV, reporting standards outlined in Domain 4 are also
applicable.
There are some key issues that need to be considered in the trans-
mission dynamics of HPV models of MSM. These include consideration
of whether the infection of multiple anatomic sites and/or the sex role
separation (insertive vs receptive intercourse) should be made explicit,
the typically high variance in MSM contact rates, how to define viral
transmissibility in terms of mode and type (per-partnership or per-
contact transmissibility) and how to model prevalence by age.
Modelling networks including consideration of bisexual men is required
to fully capture the potential effects in MSM of some herd protection
which may be derived from female vaccination.
Only a few trials to date have assessed vaccine efficacy in MSM
[47–49]. Models considering the incremental benefit of universal male
vaccination in addition to universal female vaccination should ideally
take into account the disease burden in MSM versus exclusively het-
erosexual men and lower herd protection (from female vaccination) for
MSM compared to exclusively heterosexual men. Ignoring this would
yield a conservative estimate for the incremental benefit of both uni-
versal boys and targeted MSM vaccination (compared to female-only
vaccination). Models of targeted MSM vaccination should likewise
consider whether universal male vaccination is also taken into account
as part of the comparator - this will depend on the vaccination program
in place, the age groups targeted for immunization and the time horizon
of the analysis. The route by which vaccines can be delivered to MSM
are decidedly different from those for vaccination of adolescents or
adult women, with implications in terms of vaccine coverage by age
that need to be considered, possibly drawing on delivery mechanisms
and coverage levels achieved for other selective MSM vaccination
programs such as hepatitis B vaccination.
HPV-FRAME reporting standards for cost-effectiveness models of
targeted HPV vaccination in MSM are presented in Appendix Table A4.
An example application to an evaluation of targeted HPV vaccination of
MSM in the UK [50] is presented in Appendix Table A5.
7. Domain 4. modelled evaluations of HPV vaccination or cervical
cancer screening in individuals living with HIV (ILWH)
Women living with HIV have higher HPV acquisition risks [51,52],
decreased clearance of HPV and precancerous lesions [52,53], in-
creased progression to high-grade pre-cancer [54,55], higher cervical
cancer incidence [56] and higher cervical cancer-related mortality
compared to HIV-negative women [57]. Antiretroviral therapy (ART)
for HIV can decrease the risk of cervical cancer, but this benefit is likely
dependent on early ART initiation and sustained viral suppression
[58,59]. Both the bivalent and quadrivalent vaccine have been eval-
uated for efficacy in HIV-infected women [60–62].
Similarly, in men infected with HIV, HPV acquisition and pre-
valence of anal oncogenic HPV infections is higher [63,64], HPV per-
sistence is greater [65], HPV clearance is decreased [64] and there is an
increased progression to high-grade anal intraepithelial neoplasia (AIN)
[66] and an increased risk of anal cancers [67]. The evidence regarding
the impact of ART on AIN in men living with HIV is contradictory. Some
studies have not found greater protection against AIN [68] or an impact
on the natural history of AIN with use [68–70] whereas others have
found that prolonged use of ART (> 2 years) is associated with a re-
duced risk of high-grade AIN [71,72].
Key considerations for modelling HPV-associated cancers in ILWH
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are presented in Appendix Table A6 and include capturing differences
in HPV pathogenesis by HIV status. Relative risks can be used as mul-
tipliers to increase rates of HPV acquisition, persistence and progression
for ILWH [73]. This approach would have the benefit of also capturing
disparities in access to care; ILWH with low counts of CD4 T lympho-
cytes are at the highest risk of precancer and HPV-associated cancers
but are likely to have the lowest access to HIV care including cancer
screening. Protocols for cervical and anal cancer screening and HPV
vaccination can differ by HIV status; and, for outcomes among ILWH,
these should be reflected in the model design and parameterization.
Evaluations involving men living with HIV may also need to consider
reporting standards presented for Domain 3 (MSM).
This domain is an emerging area in the literature; although some
evaluations have been performed [74,75] an example has not been
provided for this type of evaluation.
8. Domain 5. additional issues in reporting modelled evaluations
in LMIC
Questions regarding the comparative and cost-effectiveness of HPV
prevention strategies are most pressing in low- and middle-income
countries (LMIC), where the burden of HPV-related disease is greatest.
These questions have motivated a growing number of model-based
analyses to date, which have focused primarily on cervical cancer
screening strategies and evaluations of HPV vaccination alone or with
screening. Screening 1–3 times per lifetime between the ages of 30–50
years has been reported to be cost-effective in many LMIC evaluated
and primary HPV testing is predicted to be more effective when com-
pared to cytology or visual inspection with acetic acid [76–79]. Fur-
thermore, HPV vaccination of adolescent girls with bivalent, quad-
rivalent or nonavalent HPV vaccine is likely to be cost-effective in LMIC
at low vaccine prices (e.g. prices available to Gavi, the Vaccine Alliance
and the Pan American Health Organisation Revolving Fund) [27]. The
opportunity to pair vaccination with some screening in adulthood has
also been shown to be promising in some countries [18,80–95].
Screening has also been found to be cost-effective in several analyses of
HIV-infected women and populations with a high burden of HIV
[96–98].
For models evaluating HPV prevention in LMIC there is still un-
certainty regarding the burden of disease, as well as the health impact
and the costs of delivering health interventions. In terms of costs, the
WHO states that a fixed cost–effectiveness threshold should never be
used as a stand-alone criterion for decision-making; although cost-ef-
fectiveness ratios are informative they also need to be considered
alongside affordability, budget impact, fairness, feasibility and any
other criteria considered important in the local context [99].
In addition to the rigorous reporting guidelines specified in the
general framework, additional key parameters and assumptions for
models of HPV prevention in LMIC are listed in Appendix Table A7. An
example application to an evaluation of the comparative and cost-ef-
fectiveness of HPV-based cervical cancer screening algorithms in El
Salvador [77] is presented in Appendix Table A8. Outputs were also
reported as per core reporting standards (Table 4). It should be noted
that the WHO is currently drafting a strategic plan for cervical cancer
elimination, which specifies goals and targets for vaccination, cervical
screening (twice in a lifetime) and pre-cancer and cancer treatment
scale-up in LMIC. Ongoing modelling is supporting the estimates of
impact and cost-effectiveness of the WHO strategic elimination plan.
9. Domain 6. framework for models of cervical screening, in
unvaccinated and vaccinated populations and integrated cervical
screening and HPV vaccination approaches
Cervical screening using cytology has been the basis for reducing
cervical cancer incidence and mortality rates in high-income countries
over the last several decades. However, two developments have
required screening to be re-evaluated in many countries. The first is the
emergence of a wealth of evidence on the improved sensitivity of HPV
DNA testing compared to cytology for detection of precancerous lesions
and the second has involved the large-scale deployment of prophylactic
HPV vaccination [100].
Cervical screening evaluations consider many policy alternatives
including cytology technologies (conventional vs. liquid-based cy-
tology), HPV testing vs. cytology vs. co-testing using both technologies,
different test technologies for HPV screening, different triaging ap-
proaches for screen-positive women, and the role of self-collection for
HPV testing as a screening approach. A newer challenge has involved
the need to evaluate cervical screening in the context of HPV vacci-
nation, which requires the complex interactions between the two pre-
ventative mechanisms to be simulated. Cohorts of women who have
been vaccinated against HPV in various countries are entering the
target cervical screening age range. Over the next few decades, the risk
of CIN2+ in vaccinated age cohorts will be substantially lower than in
unvaccinated age cohorts and will additionally decrease over time be-
cause of increasing herd effects, the introduction of new vaccines and
potentially increased vaccine uptake in the future. Prospective studies
alone do not provide sufficient guidance to policy makers, and in-
tegrated vaccination-screening models are needed to project the long-
term effects and value of vaccination with continued screening.
A recent systematic review of model-based cervical screening eva-
luations [10] identified only a small number of screening evaluations
conducted for vaccinated women. Some evaluations have found that
cervical screening below the age of 25 years in vaccinated cohorts is
unlikely to be cost-effective [101–106].
Primary HPV screening is likely to be cost-effective in screening
cohorts vaccinated with either the bivalent or quadrivalent HPV vac-
cine when the screening interval is at least 5 years [101–106]. It has
also been reported that cervical lesions arising from HPV infections
from types other than HPV16/18 have a lower progression rate than
HPV16/18 [107] and are associated with a low recurrence disease rate
[108]. For certain countries, evidence in vaccinated women of reduc-
tion in cervical pre-cancer and/or cancer is likely to be the impetus for
changing their approach to screening for these women.
Natural history; algorithms for screening, surveillance, treatment,
and post-treatment; adherence to screening and follow-up re-
commendations; and test characteristics are key areas to consider in
cervical screening evaluations. It is recommended that the following
parameters are reported: screening, triage, surveillance, and treatment
algorithms; screening and follow-up adherence; test characteristics;
calibration and/or validation with screening turned on (against
screened population outcomes); and comparisons to other models an-
swering a similar question as a form of model corroboration.
HPV-FRAME reporting standards for models that examine the im-
pact of cervical screening alone, in either vaccinated or unvaccinated
women, adapted from previous work [109], are presented in Appendix
Table A9. The Reported Data should clarify that each reporting stan-
dard should encompass both primary and secondary tests, when re-
levant. Additional reporting standards for models that examine the
combined impact of combinations of cervical screening and vaccination
are presented in Appendix Table A10. An example application of the
framework to an evaluation of primary HPV testing versus cytology-
based cervical screening in women in Australia, both vaccinated for
HPV and unvaccinated [110] is presented in Appendix Table A11.
9. Domain 7. Additional issues for reporting models of alternative HPV
vaccines and reduced-dose schedules
With the availability of alternative HPV vaccines, strong evidence
for the efficacy of two-dose schedules and increasing signs of promise of
one-dose schedules, model-based analyses have emerged to address
these questions. Key drivers of reduced dose evaluation outcomes in-
clude their lower costs and the duration of vaccine protection which is a
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function of waning as protection must be maintained during key ages of
sexual activity. A long duration of vaccine efficacy is required in order
for a reduced-dose schedule to yield substantial benefits, although these
may differ by country, depending on sexual behaviour, age-mixing and
other cofactors. Analyses for reduced-dose schedules are subject to the
same reporting guidelines as specified in the general framework;
however, HPV-FRAME provides additional reporting guidelines for
comparative evaluations of different vaccine types and reduced-dose
schedules. Comparative vaccine or dose evaluations that have been
performed to date include bivalent versus quadrivalent HPV vaccines
[14,111]; bivalent or quadrivalent HPV vaccines versus nonavalent
[112]; and 1-dose versus 2-doses versus 3-doses of the HPV vaccine
[113,114]. These evaluations have concluded that the cost threshold for
the additional amount that could be paid for higher valency vaccines in
high-income countries like the USA or the UK is US$50 per dose for the
quadrivalent HPV vaccine (versus bi-valent) [14,111] and ~US$18–28
per dose for the nonavalent HPV vaccine (versus the bi- or quadrivalent
vaccine) [115,116] or ~$3 per dose in low to middle income countries
(LMIC) [83]. Fewer doses can be more cost-effective than a 3-dose re-
gimen but that is dependent on assumptions regarding the duration of
vaccine protection of a reduced-dose schedule, which needs to be at
least 20 years [114,117].
HPV-FRAME reporting standards for models of alternative HPV
vaccines and reduced-dose schedules are presented in Appendix Table
A12. An example application of an evaluation presenting a comparison
of two dose and three dose HPV vaccine schedules [114] is presented in
Appendix Table A13.
10. Conclusions and next steps
The HPV-FRAME initiative aims to complement general principles
of good modelling practice as articulated by ISPOR, and other model-
ling guidelines via the provision of specific guidance on issues of re-
levance in HPV modelling. Ensuring clear reporting of HPV prevention
models through the use of HPV-FRAME will allow the end-user to judge
a model's validity, ascertain areas of simplification and whether these
were appropriate to the decision question, and assess the degree of
uncertainty in a decision process. Overall, the use of the framework
should increase the quality and standard of reporting evaluations of
HPV prevention.
HPV-FRAME was developed by a core steering committee, with
input from contributors from the wider HPV expert community who
expressed an interest in participating in the initiative. It is possible that
under a different panel of contributors some of the parameters included
in the current framework may have varied to a certain degree.
However, the framework was based on the identification of sources of
bias and quality issues from systematic review of the relevant literature
and has been developed by modellers within the HPV modelling com-
munity using a well-established process.
HPV modelling is a dynamic field with new data and evidence
emerging. There is still a large amount of uncertainty in many of the
inputs to models of HPV prevention. For example, in relation to models
of alternative HPV vaccines and reduced-dose schedules the relative
properties among the different vaccines and the level of protection with
reduced-dose schedules has not been fully determined. Model-based
analyses can integrate the existing evidence and explore these un-
certainties to provide timely input to decision making. However, it is
incumbent upon the investigators to clearly specify the assumptions
regarding these uncertainties in order to improve transparency, which
has been the motivation for HPV-FRAME. To account for changes and
other issues such as the possibility of a specified repository for models’
documentation, we aim to review and update HPV-FRAME regularly
through a review of the recent literature and input received from in-
terested parties through the dedicated HPV-FRAME website (http://
www.hpv-frame.org).
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Appendix
Table A1
HPV-FRAME reporting standards for models of vaccination in adolescent individuals.
a) Inputs Reported?
(Y/N)
Reported by
age? (Y/N)
Report by sex? Comments
Vaccine uptake Y Y Y Uptake by number of doses, age, sex
Vaccine efficacy Y Y Y Efficacy by number of doses, age, sex, HPV type
Vaccine cross-protection Y N/A N/A Level and duration of protection by dose and type.
(continued on next page)
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Table A1 (continued)
a) Inputs Reported?
(Y/N)
Reported by
age? (Y/N)
Report by sex? Comments
Duration vaccine protection and waning Y Y Y (report by sex and
site/disease if applic-
able)
Duration of vaccine protection and waning assumptions. Report base case
assumption and sensitivity analysis on duration of protection
Vaccine and delivery costs Y Y (if applic-
able)
Y (if applicable) Vaccine-related cost assumptions (by sex if they differ) including infrastructure
(overhead), administration, cost per dose. Delivery mechanism
Pre-vaccination disease burden (including
population attributable fractions for H-
PV)
Y Y Y (if applicable) Pre-vaccination disease burden included when assessing effect on infections and
cancer or pre-vaccination cancer burden for population attributable fractions.
Duration of natural immunity Y Y Y Comment on waning function
b) Outputs Reported?
(Y/N)
Report by
age? (Y/N)
Report by sex? (B, F,
or M)
Report as calibration or validation target? (Y/N)
Absolute reductions in HPV infections, and/
or warts, post-vaccination
Y Y As appropriate to
evaluation
Y
Absolute reductions in CIN2+ post-vaccina-
tion
Y Y As appropriate to
evaluation
Y. Suggested comparison to vaccine trial data; consideration should be given to
trial-based modelling to support this validation process, and/or comment should
be made on the applicability and external validity of the trial data to the situation
being modelled.
Absolute reductions in invasive cancer (cer-
vical and other HPV cancers, as relevant)
post-vaccination
Y Y As appropriate to
evaluation
Y
B: both sexes; CIN2+: cervical intraepithelial neoplasia grade 2 and above; F: female; male; N: no; Y: yes.
Table A2
Application to Jit et al. (2008) [37].
a) Inputs Reported? Reported by
age? (Y/N)
Reported by sex? Comments
Vaccine uptake Y Y Y
Vaccine efficacy Y Y (implicitly) Y (implicitly) Assumed 100% independent of sex and age
Vaccine duration and waning Y Y (implicitly) Y (implicitly) Assumed independent of sex and age
Vaccine and delivery costs Y Y Y
Pre-vaccination disease burden (including PAFs) Y Y Y In accompanying paper (Jit et al., 2010; Choi et al., 2010)
Heterogeneity in sexual behaviour Y Y Y Reported by age, sex and risk group (Choi et al., 2010)
Duration of natural immunity Y Y Y
b) Outputs
Absolute reductions in HPV infections, cervical and other HPV-
related cancers and/or warts, post-vaccination
Y N Implicitly (cer-
vical)
N (warts/non-cer-
vical cancers)
Outputs considered: cervical (F); warts (F + M); non-cervical
cancers (F + M; sensitivity analysis)
Absolute reductions in CIN2+ post-vaccination Y N Y (implicitly)
Absolute reductions in invasive cancer post-vaccination Y N Y(Implicitly)
F: female; M: male; N: no; PAFs: population attributable fractions; Y: yes.
Table A3
HPV-FRAME reporting standards for evaluations of vaccination at older ages∗.
Inputs Detail How to report Report by
sex?
Natural his-
tory
Nature history structure used in the model (including progression and
regression from high grade to low grade disease/productive HPV infec-
tion).
Report progression status by age and/or by time since infection and HPV
type. (Comment on whether progression rates change according to time
since HPV infection or by age).
As appro-
priate to
evaluation
Rate of clearance of HPV infection Report by age and/or by time since infection and HPV type As appro-
priate to
evaluation
Rate of loss of naturally acquired immunity Report by age and/or by time since infection and HPV type As appro-
priate to
evaluation
Simulation of latency by HPV type (handling of apparently new infections
in older women – is the possibility that some are reactivated latent
infections explored in sensitivity analysis?)
Report proportional reduction in true HPV incidence, by age or time
since infection and HPV type. Also report assumptions about re-activated
latent infection (i.e. whether there is differential progression to precancer
or cancer)
As appro-
priate to
evaluation
Vaccination∗ Vaccine coverage at older ages Report by age
(continued on next page)
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Table A3 (continued)
Inputs Detail How to report Report by
sex?
As appro-
priate to
evaluation
Whether screen-and-vaccinate is being modelled, or just vaccination at
older ages (without linking to screening/HPV status)
Report screening strategy (if any including screening and triage test,
interval and age-range and management strategy for those who are
vaccinated)
As appro-
priate to
evaluation
∗ HPV-FRAME core reporting standards and reporting standards for models of vaccination in adolescent individuals (Table A1) are also applicable.
Table A4
HPV-FRAME reporting standards for cost-effectiveness models of vaccination in MSM.∗
a) Inputs Reported? (Y/
N)
Report by Age?
(Y/N)
Comments
MSM-specific disease burden Y Y State where incidence rates have been derived from
Interaction between HIV and HPV Y Y If HIV is modelled state what interactions are included: risk of infection, risk of
progression etc.
HIV prevalence Y Y Report for HIV-positive and negative individuals
Vaccine coverage Y Y
Prior exposure Y Y If modelled or assumed
b) Outputs Reported? (Y/
N)
Report by Age?
(Y/N)
Report as calibration or validation target? (Y/N)
Reduction in disease incidence Y Y Y
Impact assessment (e.g. relative and absolute reductions in d-
isease outcomes)
Y N Y. State outcomes by cancer type or whether composite outcome measures
MSM: men who have sex with men; N: no; Y: yes.
∗ HPV-FRAME core reporting standards are also applicable.
Table A5
Example application of HPV-FRAME guidelines to Lin et al., 2016 [50].
Inputs Reported? (Y/
N)
Report by Age?
(Y/N)
Comments
MSM-specific disease burden Y Y Incidence rates by age derived from registries combined with population attributable fractions and relative risks
HIV prevalence Y Y Split by diagnosed and undiagnosed
Time from HPV infection to
cancer
Y N Natural history model for anal cancer giving rate of progression to cancer precursors and cancer. Proportionate
outcomes for other cancers
Vaccine coverage Y Y Age bands 16–25, 16–30, 16–35, 16-40y, 50% among GUM attenders (16.7% of all MSM)
Prior exposure Y Y (implicitly) Estimated by transmission-dynamic model
Reported?
(Y/N)
Report by
Age (Y/N)
Report as calibration or vali-
dation target? (Y/N)
Comments
Reduction in disease in-
cidence over time
Y Y Y (provided post-vaccine data
are available)
Separate projections of annual diagnoses of anogenital warts and cancers over time
Impact assessment by
disease outcome
Y N N Reported by age for anal cancer and warts; reported as totals for other cancers. Cost-
effectiveness analyses only provided for composite outcome measures
GUM: genitourinary medicine clinics; PP: per protocol; N: no; Y: yes.
N: no; Y: yes.
Table A6
HPV-FRAME reporting standards for models of HPV-associated cancers among individuals living with HIV (ILWH).∗
a) Inputs Reported?
(Y/N)
Report by age?
(Y/N)
Report by sex? Y/N (B,
M, F)
HPV prevalence, CIN prevalence and cervical cancer incidence by HIV status Y Y Y (implicitly)
HPV disease multipliers on HPV acquisition, progression from HPV infection to cancer (or relevant precursors, if
modelled) for HIV-infected women/men
Y If applicable Y (implicitly)
HPV-associated cancer mortality by HIV status (and CD4 count if modelled) Y Y Y
Relevant co-morbidities Y N Y
HPV-associated screening sensitivity/specificity by HIV status Y If applicable Y (implicitly)
(continued on next page)
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Table A6 (continued)
a) Inputs Reported?
(Y/N)
Report by age?
(Y/N)
Report by sex? Y/N (B,
M, F)
b) Outputs
Reduction in cervical cancer incidence over time by HIV status (and CD4 count and ART status if modelled) Y Y Y (implicitly)
ART: Antiretroviral therapy; CIN: cervical intraepithelial neoplasia; CD4: CD4 T lymphocytes; HIV: human immunodefiency virus; N: no; Y: yes.
∗ HPV-FRAME core reporting standards are also applicable.
Table A7
Additional HPV-FRAME reporting standards for models of HPV prevention in LMIC.# ∗
Inputs Reported?
(Y/N)
Report by
Age? (Y/N)
Report by
sex? (Y/N)
Comment
HIV prevalence rates, if endemic in country Y N Y
Description of any opportunistic or pilot/demon-
stration screening projects ongoing
Y Y Y
Costs Y N N Currency conversion (e.g., PPP, tradeable versus non-tradeable), indicative will-
ingness to pay threshold to help inform decision making.
Abbreviations: PPP: purchasing, power, parity.
# Models need to specify whether data came from the country for which the evaluation is conducted or whether the data was extrapolated from another setting. If
data is extrapolated, the method used to do so needs to be described.
∗ HPV-FRAME core reporting standards are also applicable.
Table A8
Example application of HPV-FRAME guidelines to Campos et al. (2015) [77].
Inputs Reported? (Y/
N)
Reported by Age?
(Y/N)
Reported by sex? (B, F, M) Comment
HIV prevalence rates N N N
Description of any opportunistic or pilot/demonstration
screening projects ongoing
Y Y F-only Pap every 2 years
Costs Y N F-only Currency conversion: NA (local currency
costs=US$)
Outputs† Report by
Age?(Y/N)
Report by sex? (B,
F, M)
Report as calibration or validation
target? (Y/N)
Comments
HPV prevalence, pre-intervention Y F-only Y Used for calibration
Prevalence of HPV16 and HPV18 in cervical cancer N F-only Y Used for calibration
Cervical cancer incidence Y F-only Y Used for validation
Relative reduction in lifetime risk of cervical cancer N F-only N HPV screen-and-treat reduced lifetime
cancer risk by 60%.
Total lifetime cost N F-only N 2012 US$
Life expectancy N F-only N Discounted life expectancy
Incremental cost-effectiveness ratio N F-only N 2012 US$/year of life saved.
B: both sexes, F: female only; M: male only.
† Outputs reported here for illustrative purposes.
Table A9
HPV-FRAME reporting standards for models of cervical screening.∗
Inputs Reported?
(Y/N)
Report by age?
(Y/N)
Comment∗∗
Routine screening behaviour (routine and f-
ollow-up and test-of-cure)
Y Y Screening age-group, percentage of women who are never screened, and percentage of women not
screened.
Clinician-collected vs self-collected sample
Organisation of screening (opportunistic vs programmatic)
Proportion attending (or rate) screening for each age group at specified interval cycles (on-time
screening)
Proportion attending (or rate) screening beyond screening intervals i.e. over-screening (important for
costs)
Screening test(s) and colposcopy accuracies Y N Report by test result: cytology grade for cytology or HPV type for HPV tests; report on sensitivity and
specificity or equivalent specification if test accuracy.
Proportion unsatisfactory tests
(continued on next page)
K. Canfell, et al. Papillomavirus Research 8 (2019) 100184
11
Table A9 (continued)
Inputs Reported?
(Y/N)
Report by age?
(Y/N)
Comment∗∗
Abnormal test management (primary and tr-
iage)
Y N Distinction of result grade (e.g. cytology grade).
Separate management by test result
Sensitivity and specificity values of cytology or other test result
Diagnostic follow-up of abnormal tests Y N Indication of diagnostic follow-up
Distinct colposcopy and biopsy outcomes
Sensitivity and specificity values of colposcopy
Management by disease grade (confirmed d-
isease)
Y N Indication of HSIL management
Distinct HSIL management approaches
Treatment efficacy of treated HSIL
Follow-up of treated disease
Sources of information for screening struc-
ture and parameterization
Y N Guidelines
Survey or surveillance
Expert opinion/personal communication
Assumption
Abbreviations: HSIL: high grade squamous intraepithelial neoplasia
∗ HPV-FRAME core reporting standards are also applicable.
∗∗ Each reporting standard should encompass both primary and secondary tests, where relevant.
Table A10
Additional HPV-FRAME reporting standards for integrated models of cervical screening and vaccination.∗
Inputs Reported?
(Y/N)
Report by
age? (Y/N)
Report by sex?
(B, F, M)
Comments
HPV type incidence, clearance
and progression rates
Y Y F HPV16 and HPV18 need to be modelled separately. HPV31/33/45/52/58 need to be modelled
separately when evaluating screening in cohort vaccinated with 9-valent vaccine or when cross-
protection from 2/4-valent vaccine is assumed.
Herd effect Y Y F
Association between vaccina-
tion and screening uptake
Y Y F
Screening test(s) and colpo-
scopy accuracies
Y N F Report by test result: by grade for cytology; by HPV type for HPV tests; report on sensitivity and
specificity or equivalent specification if test accuracy.
Proportion unsatisfactory tests
Fixed – variable costs∗ Y N F Report all vaccine cost assumptions including system-level infrastructure, administration, cost per
dose, cost per vaccinated individual
B: both sexes; F: female; M: male; N: no; Y: yes.
∗ HPV-FRAME core reporting standards are also applicable.
Table A11
Example application of HPV-FRAME guidelines to Lew/Simms et al., 2017 [110].
Inputs Reported?
(Y/N)
Reported by
age? (Y/N)
Comments
Routine screening behaviour Y Y Screening age-group: the strategies evaluated involve:
-2y conventional cytology-based screening for women 18-69 years (comparator); 3y cytology screening for
women aged 25-49 years combined with 5-yearly cytology screening for women aged 50-64 years; 5-yearly
primary HPV screening for women aged 25-64 years
- The modelled age-specific screening attendance rate for comparator strategy (i.e. current program) was
based on the analysis of Victoria Cytology Cervical Register data; rates modelled for other screening
strategies were derived from the currently observed Australian data and informed by other countries’
experience
- 2.1% for conventional Pap smear and 1.8% for manually-read or image-read cytology.
Abnormal smear management Y N - Cytology results was separated into 5-grades: negative, ASC-US (pLSIL), LSIL, ASC-H (pHSIL), HSIL+
- Different management was modelled for negative, low-grade and high-grade cytology results
- For CIN2+ detection at ASC-US threshold:
Conventional cytology: 74.1% (sensitivity), 95.7% (specificity)
Manually-read LBC: 74.1% (sensitivity), 94.7% (specificity)
Image-read LBC: 81.2% (sensitivity), 94.5% (specificity).
For CIN3+ detection at ASC-US threshold:
Conventional cytology: 75.6% (sensitivity), 95.3% (specificity)
Manually-read LBC: 83.9% (sensitivity), 94.3% (specificity)
Image-read LBC: 80.0% (sensitivity), 96.6% (specificity)
Diagnostic follow-up of Y N -Indication of diagnostic follow-up stated
abnormal cytology - Colposcopy outcomes including unsatisfactory, satisfactory and normal, and satisfactory and abnormal.
Biopsy outcomes including negative/HPV infected, CIN2, CIN2/3 and cervical cancer.
(continued on next page)
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Table A11 (continued)
Inputs Reported?
(Y/N)
Reported by
age? (Y/N)
Comments
- The modelled colposcopy positive rate are 40.2% for women without CIN, 76.5% for women with CIN1,
and 88.4% for women with CIN 2 or worse
- Follow-up of treated disease: Annual follow-up with HPV and cytology co-testing until the woman
obtained negative outcome on both test in two consecutive 12 months follow-up visit (test-of-cure)
Inputs Reported? Reported by
age (Y/N)
Lew/Simms et al, 2017
Management by CIN grade Y N - Indication of CIN management stated
- Distinct CIN management approaches: women with negative histology outcome or CIN1 were referred to
follow-up; women with CIN2/3 were referred to precancer treatment.
- Treatment efficacy of treated CIN: 100% (assumed a 10% failure rate in the first treatment but all women
with unsuccessful treatment were assumed to be identified and had successful second treatment)
Sources of information for screening s-
tructure and parameterisation
Y N Australian National Health and Medical Research Council (NHMRC) 2005 guideline and the new clinical
management guidelines that developed in 2015–16 to support the new National Cervical Cancer Screening
Program were modelled.
Survey/ surveillance:
- The Victorian Cytology Cytology Register data was analysed to inform the screening coverage, and the
proportion of early-screening, ‘on-time’ screening and late-screening.
- Colposcopy data collected at Royal Women Hospital was used to inform the compliance rate to colposcopy
follow-up and colposcopy accuracy.
- Screening outcomes reported in the annual National Cervical Cancer Screening Program monitoring report
(i.e. age-specific proportion of cytology test with low-grade and/or high-grade outcomes, age-specific
proportion of women with abnormal high-grade histology per 1,000 women screened etc) were used to
calibrate/validate model’s screening outcome.
- Age-specific cervical cancer incidence and mortality rate reported by the Australian Institute of Health and
Welfare was used for model calibration.
- Cost was assumption was informed by Australian Medical Benefit Scheme; assumption were made where
applicable
- HPV vaccination coverage was modelled based on the National HPV Vaccination Program Register data.
- Expert opinion of the Renewal Steering Committee was seek for management that was not specified in the
guideline for cervical screening.
Cost of manually-read LBC, image-read LBC and HPV test (when it was used as primary screening test) were
based on assumption
ASC-H: atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion; CIN: cervical intraepithelial neoplasia; HSIL: high-grade squamous
intraepithelial lesion; LBC: liquid based cytology; LSIL: low-grade squamous intraepithelial lesion; pHSIL: possible high-grade squamous intraepithelial lesion; pLSIL:
possible low-grade squamous intraepithelial lesion.
Table A12
HPV-FRAME reporting standards for evaluations assessing alternative vaccine types or reduced-dose schedules.∗
a) Inputs Reported?
(Y/N)
Report by
Age? (Y/N)
Report by sex?
(B, F, M)
Comments
Vaccine efficacy/wa-
ning
Y Y Y Level and duration of protection (waning function) by dose, type, age. (For 2-dose regimen: specify if each
dose received is modelled and the efficacy modelled for each dose).
Timing between do-
ses (for 2-dose)
Y N/A Y
Vaccine cross-pro-
tection
Y N/A N/A Level and duration of protection by dose and type
Cost Y N/A N/A Cost per dose, cost per vaccinated individual, and all vaccine cost assumptions including infrastructure,
administration.
b) Outputs Reported?
(Y/N)
Report by
Age? (Y/N)
Report by sex?
(B, F, M)
Report as calibration or validation target? (Y/N)
Threshold cost per
dose
Y N/A N/A
B: both sexes, F: female only; M: male only; N: no; N/A: not applicable; Y: yes.
∗ HPV-FRAME core reporting standards are also applicable.
Table A13
Example application of HPV-FRAME guidelines to Jit et al., 2015 [114].
Inputs Reported?
(Y/N)
Report by Age?
(Y/N)
Report by sex? (B,
F, M)
Comments
Y Y (implicitly) N/A
(continued on next page)
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Table A13 (continued)
Inputs Reported?
(Y/N)
Report by Age?
(Y/N)
Report by sex? (B,
F, M)
Comments
Vaccine efficacy/waning (by
dose, type)
Full protection against 16/18 (2- and 3-dose)
Waning: 10, 20 or 30 years for 2-dose with exponential or uniform waning functions
Age dependency: 2-dose regime only given to 12-year olds in modelled scenarios.
Timing between doses (for 2-
dose)
Y N/A N/A 2-dose regime only given to 12-year olds in modelled scenarios.
Vaccine cross-protection (by
dose, type)
Y Y (implicitly) N/A Partial efficacy against 31/33/45/52/58 assumed for 2- and 3-dose; sensitivity analysis with
no cross-protection for 2-dose
Cost per dose/per vaccinated
individual
Y N N/A Cost per dose assumed constant
Output Reported?
(Y/N)
Report by Age?
(Y/N)
Report by sex? (B,
F, M)
Report as calibration or validation target? (Y/N)
Threshold cost per dose N N N
B: both sexes, F: female only; M: male only; N: no; Y: yes.
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